RxDoctor Payments Data

Charles Taylor, MD

Family Medicine · Atlanta, GANPI 1275540726

Payments from drug & device makers

$3,996in general payments, 2019–2025

Across 204 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$809
  • Novo Nordisk$547
  • Lilly USA, LLC$411
  • Pfizer$272
  • Amgen$239
  • AstraZeneca$221
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,97199%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,996 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$46,295
Medicare patients
191
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$45,213
EliquisApixaban38$35,672
MounjaroTirzepatide29$28,938
JanuviaSitagliptin Phosphate11$17,644
JardianceEmpagliflozin15$15,418
Repatha SureclickEvolocumab12$6,040
Rosuvastatin Calcium411$4,827
PaxlovidNirmatrelvir/Ritonavir17$4,288
SynthroidLevothyroxine Sodium28$2,966
Atorvastatin Calcium242$2,784
Ezetimibe103$2,432
Pregabalin22$2,137
Olmesartan Medoxomil35$1,886
Esomeprazole Magnesium33$1,614
Pantoprazole Sodium76$1,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$547$45,21346 claims
PfizerEliquis, Paxlovid$272$39,96055 claims
Lilly USA, LLCMounjaro$411$28,93829 claims
MerckJanuvia$46$17,64411 claims
Boehringer IngelheimJardiance$195$15,41815 claims
AbbVieSynthroid$169$2,96628 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,209128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →